For patients not currently taking lubiprostone (Amitiza®), non-formulary lubiprostone (Amitiza®) will be covered on the prescription drug benefit when the following criteria are met:

1. Diagnosis of irritable bowel syndrome with constipation (IBS-constipation predominant) in women 18 years of age and older ONLY

   - AND -

   • Patient has had an inadequate response to an adequate trial of at least 4 weeks or intolerance to scheduled doses of the following medications:
     - Fiber supplement: Psyllium fiber (Metamucil, Konsyl) or methylcellulose (Citrucel)
     - Polyethylene glycol (MiraLAX)
     - Linaclotide (Linzess®) (also criteria based)

   - OR -

2. Diagnosis of chronic idiopathic constipation

   - AND -

   • Patient has had an inadequate response to an adequate trial of at least 4 weeks or intolerance to scheduled doses of the following medications:
     - Fiber supplement: Psyllium fiber (Metamucil, Konsyl) or methylcellulose (Citrucel)
     - An osmotic laxative: polyethylene glycol (MiraLAX) or lactulose
     - A stimulant laxative: senna or bisacodyl
     - Linaclotide (Linzess®) (also criteria based)

   - OR -
Criteria Based Consultation Prescribing Program

CRITERIA FOR DRUG COVERAGE

lubiprostone (Amitiza®)

3. Diagnosis of opioid induced constipation in an adult with an active opioid prescription

- AND -

- Medication is being prescribed by an Oncologist or a Hospice/Palliative Care clinician for a patient currently enrolled in Hospice or Palliative Care program, or after consultation with a Pain Management Specialist

- AND -

- Patient has failed a trial of at least 2 weeks or has an intolerance or contraindication to scheduled dosing of the following medications, used in combination with other agent(s) with different mechanism of action^ and route of administration:
  - polyethylene glycol (MiraLAX),
  - lactulose or sorbitol,
  - senna
  - bisacodyl

- AND -
  - naldemedine (Symproic) (also criteria based)

These agents should be used in regularly, in combination, to be effective in management of opioid-induced constipation.

^ e.g. osmotic with stimulant (polyethylene glycol and senna and/or bisacodyl suppository)

For patients currently taking lubiprostone (Amitiza®), non-formulary lubiprostone (Amitiza®) will be covered on the prescription drug benefit when the following criteria are met:

1. Diagnosis of irritable bowel syndrome with constipation (IBS-constipation predominant) in women 18 years of age and older ONLY

- AND -
Criteria Based Consultation Prescribing Program

CRITERIA FOR DRUG COVERAGE

lubiprostone (Amitiza®)

- Patient has had an inadequate response to or intolerance to scheduled doses of the following medications:
  - Fiber supplement: Psyllium fiber (Metamucil, Konsyl) or methylcellulose (Citrucel)
  - Polyethylene glycol (MiraLAX)
  - Linaclotide (Linzess®) (also criteria based)

- OR -

2. Diagnosis of chronic idiopathic constipation

- AND -

- Patient has had an inadequate response to or intolerance to scheduled doses of the following medications:
  - Fiber supplement: Psyllium fiber (Metamucil, Konsyl) or methylcellulose (Citrucel)
  - An osmotic laxative: polyethylene glycol (MiraLAX) or lactulose
  - A stimulant laxative: senna or bisacodyl
  - Linaclotide (Linzess®) (also criteria based)

- OR -
Criteria Based Consultation Prescribing Program

CRITERIA FOR DRUG COVERAGE

lubiprostone (Amitiza®)

3. Diagnosis of opioid induced constipation in an adult with an active opioid prescription

-AND-

- Medication is being prescribed by an Oncologist or a Hospice/Palliative Care clinician for a patient currently enrolled in Hospice or Palliative Care program, or after consultation with a Pain Management Specialist

-AND-

- Patient has failed a trial of at least 2 weeks or has an intolerance or contraindication to scheduled dosing of the following medications, used in combination with other agent(s) with different mechanism of action^ and route of administration:
  - polyethylene glycol (MiraLAX)
  - lactulose or sorbitol
  - senna
  - bisacodyl
  - naldemedine (Symproic) (also criteria based)

These agents should be used in regularly, in combination, to be effective in management of opioid-induced constipation.

^ e.g. osmotic with stimulant (polyethylene glycol and senna and/or bisacodyl suppository)